Adaptimmune

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Type
Public
HQ
Philadelphia, US
Founded
2008
Size (employees)
173 (est)
Adaptimmune was founded in 2008 and is headquartered in Philadelphia, US

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia and Milton
Philadelphia, US (HQ)
2010 Market St
Milton, GB
Park House Park Dr

Adaptimmune Financials and Metrics

Adaptimmune Financials

Adaptimmune's revenue was reported to be $9 m in FY, 2016
USD

Revenue (Q3, 2017)

27.2 m

EBIT (Q3, 2017)

(5 m)

Market capitalization (13-Nov-2017)

4.4 b

Cash (30-Sep-2017)

145.3 m
Adaptimmune's current market capitalization is $4.4 b.
USDFY, 2016

Revenue

9 m

R&D expense

25.5 m

General and administrative expense

9.9 m

Operating expense total

35.4 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

2.9 m328 k2.4 m2.9 m3.5 m27.2 m

R&D expense

13.9 m16.2 m15.6 m18.6 m19.6 m24 m

General and administrative expense

5.9 m6.8 m5.4 m6.5 m7.7 m8.1 m

Operating expense total

19.7 m(23 m)(21 m)(25.1 m)(27.3 m)(32.1 m)
USDFY, 2016

Cash

158.8 m

Accounts Receivable

149.5 k

Inventories

1.4 m

Current Assets

198.8 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

163.8 m150.9 m140.4 m170.6 m122 m145.3 m

Current Assets

238.6 m218.2 m199.5 m222.9 m237.7 m253.9 m

PP&E

13.8 m13.4 m15.1 m35.1 m38.9 m39.8 m

Total Assets

261.6 m239.6 m222.6 m266 m284.3 m301.4 m
USDFY, 2016

Net Income

(23 m)

Cash From Operating Activities

(48.2 m)

Cash From Investing Activities

17.8 m

Cash From Financing Activities

17 k
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(15.6 m)(22.1 m)(18.5 m)

Accounts Payable

2.4 m2.5 m3.2 m5.2 m
Y, 2017

Financial Leverage

1.3 x
Show all financial metrics

Adaptimmune Operating Metrics

Adaptimmune's Patent Applications was reported to be 69 in FY, 2016
FY, 2016

Patents Issued

173

Patent Applications

69
Show all operating metrics

Adaptimmune Market Value History

Adaptimmune's Web-traffic and Trends

Adaptimmune Online and Social Media Presence

Adaptimmune Company Life and Culture

You may also be interested in